Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBIT Margin (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of EBIT Margin readings, the most recent being 50.78% for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 3846.0% year-over-year to 50.78%, compared with a TTM value of 0.5% through Dec 2025, up 2162.0%, and an annual FY2025 reading of 0.5%, up 2162.0% over the prior year.
  • EBIT Margin hit 50.78% in Q4 2025 for Apellis Pharmaceuticals, down from 48.67% in the prior quarter.
  • The five-year high for EBIT Margin was 1296.14% in Q4 2022, with the low at 31185.71% in Q2 2021.
  • Median EBIT Margin over the past 5 years was 57.74% (2023), compared with a mean of 1876.91%.
  • The sharpest move saw EBIT Margin surged 3027514bps in 2022, then plummeted -135388bps in 2023.
  • Year by year, EBIT Margin stood at 148.29% in 2021, then skyrocketed by 974bps to 1296.14% in 2022, then tumbled by -104bps to 57.74% in 2023, then skyrocketed by 79bps to 12.31% in 2024, then crashed by -312bps to 50.78% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 50.78%, 48.67%, and 18.65% for Q4 2025, Q3 2025, and Q2 2025 respectively.